INDICATED FOR OPIOID DEPENDENCE
An ANDA for an oral film product indicated for the treatment of opioid dependence was submitted in July 2013. The ANDA was filed by IntelGenx's U.S. based co-development and commercialization partner for this product, Par Pharmaceutical. According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
INT0040 is a CNS application indicated for the management of degenerative diseases. IntelGenx proposes the development of a fast onset of action film product for use in degenerative diseases using VersaFilm™, IntelGenx’s proprietary thin film technology. IntelGenx is currently looking for a partnership or alliance opportunity to complete development and commercialize INT0040.